HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

Miriam Oron

 

Miriam Oron

DermaBio Ltd. Jerusalem, Israel & Pittsburgh, PA, United States

Abstract Title:

Non-Invasive skin biomarker profiling for clinical disease characterization

Biography:

Miriam Oron is the CEO and co-founder of DermaBio, with over two decades of expertise across biotech, skincare, and medical devices. Holding a Ph.D. in Electrochemistry, she brings deep knowledge of product development and clinical research to drive innovation in healthcare and skincare. Throughout her career, Miriam has leveraged skin biomarker research to develop decision support systems and products for dermatologic and cosmetic treatments.

Research Interests:

The skin is increasingly recognized as a biologically active organ that interacts closely with the immune, neurological, and endocrine systems. The epidermis actively secretes a wide range of biomolecules, including mediators influenced by the skin microbiome. Many disease-associated mediators, such as cytokines, are shared across cutaneous and systemic physiological processes. Monitoring these biomarkers has the potential to provide clinically actionable information for diagnosis and disease management. Non-invasive skin sampling technologies offer a rapid, painless, and cost-effective approach for detecting these biomarkers. Over the years, we have identified distinct skin-surface cytokine signatures associated with multiple pathological conditions, as well as differences between healthy controls, lesional, and non-lesional skin. These studies have included psoriasis, type 2 diabetes, rosacea, atopic dermatitis, and chronic kidney disease (Experimental Dermatology, 2023; DOI: 10.1111/exd.15037). Our latest findings demonstrate, for the first time, the potential of skin-surface biomarkers to classify disease subpopulations within the paediatric atopic dermatitis population. In addition, we report novel correlations between skin-surface biomarker levels and clinical response to biologic therapy in patients with psoriasis. Collectively, these findings further support the utility of skin-surface biomarkers as clinically relevant indicators for disease diagnosis, patient stratification, and therapeutic monitoring, bringing this technology closer to routine clinical implementation.